Skip to content

GlobalRPh Renal Dosing Masterv6.8

Clinical interpretation | Version 6.8

Find the difference.
Keep the context.

Search documented disagreements and product cautions across the local library. Compare complete source versions on the drug page before choosing a regimen.

Search source differences

451 notes across 412 drug/product records.

How to interpret these notes

Generic name, brand, source or issueType of differenceAdded in v6.8

Clear filters Export all filtered notes

Search medication names and documented issues only. Do not enter patient information. This directory submits search filters to the server; the within-drug text finder remains a separate local feature.

A difference is not always a contradiction

Compare indication, formulation, route, population, renal method, dialysis conditions and source date. A safety update or source-quality failure is not an alternative dose. These notes are not independent clinical approval, and sources are not ranked or averaged.

451 matching notes. Showing 369-384; page 24 of 29.

dose table scope

Sacubitril / valsartan tablets (Entresto, adults)

ENTRESTO: reduced starting dose is not a permanent maintenance cap

The renal subsection changes the initial dose in severe impairment and then retains titration and kidney/potassium monitoring.

What to reconcile

Keep starting-dose eligibility separate from subsequent titration, response, potassium and renal-function surveillance.

1 source identities and dates

GlobalRPh RX List - ENTRESTO

GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Selected adult ENTRESTO starting-dose and monitoring guidance. Pediatric weight/formulation instructions remain outside this card.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v4.5.

Open / share source review Open drug and compare sources

renal measure and currency

Saxagliptin

Do not silently exchange CrCl and indexed eGFR thresholds

The retained original source uses a CrCl threshold; this RX mirror describes an indexed-eGFR threshold. They are not the same measurement.

What to reconcile

Verify the controlling product label and renal method before selecting a threshold. Older comments remain attributed.

1 source identities and dates

GlobalRPh RX List - ONGLYZA

GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Saxagliptin - ONGLYZA tablets; selected renal passages, not a complete prescribing monograph.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v5.3.

Open / share source review Open drug and compare sources

threshold ambiguity

Saxagliptin/metformin extended release (KOMBIGLYZE XR)

Initiation versus continuation and the exactly-45 wording

The source permits usual product dosing at eGFR >=45 yet says initiation at 30-45 is not recommended. Continuing below 45 requires reassessment and a saxagliptin cap.

What to reconcile

Clarify the exactly-45 endpoint and treatment phase; do not interpret the continuation allowance as unrestricted initiation. Do not round to resolve the conflict.

1 source identities and dates

GlobalRPh RX List - KOMBIGLYZE XR

GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Adult fixed-dose saxagliptin/metformin XR; initiation and continuation differ.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v4.2.

Open / share source review Open drug and compare sources

source quality hold

Selegiline orally disintegrating tablets (ZELAPAR)

RX page mixes unrelated products: renal import withheld

The retrieved ZELAPAR RX body contains unrelated GAMMAGARD LIQUID overdose/contraindication material. This is a source-integrity problem, not an opposing clinical recommendation.

What to reconcile

No RX clinical extract from that page is imported in v3.7. Read the exact ZELAPAR DailyMed summary; do not apply any immune-globulin wording to selegiline.

1 source identities and dates

Selegiline orally disintegrating tablets (ZELAPAR)

DailyMed / Bausch Health US, LLC | Source revision: June 2021
ZELAPAR orally disintegrating selegiline; not EMSAM or conventional capsules.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v3.7.

Open / share source review Open drug and compare sources

evidence gap

Sepiapterin - SEPHIENCE oral powder

Unknown renal pharmacokinetics is not evidence of no adjustment

The selected human renal PK information is unknown. Animal toxicity findings cannot supply a human renal dosing cutoff.

What to reconcile

Retain the evidence gap and seek the exact current product source; no dose is inferred.

1 source identities and dates

GlobalRPh RX List - SEPHIENCE

GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Sepiapterin - SEPHIENCE oral powder; selected renal passages, not a complete prescribing monograph.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v5.3.

Open / share source review Open drug and compare sources

population or indication

Setmelanotide subcutaneous - IMCIVREE

Severe-impairment eligibility also depends on age and weight

The severe-impairment instruction includes an additional exclusion for younger low-weight children, not simply one lower dose for everyone.

What to reconcile

This card supplies renal eligibility limits but not the complete titration. Verify age, weight, genetic indication and full product instructions before selecting a dose.

1 source identities and dates

GlobalRPh RX List - IMCIVREE

GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Subcutaneous setmelanotide for labeled genetic obesity indications; age/weight-specific renal eligibility.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v4.3.

Open / share source review Open drug and compare sources

source scope and renal guidance

Sevelamer carbonate - RENVELA tablets and powder

Before use: Sevelamer carbonate - RENVELA tablets and powder

Phosphorus concentration, meals and exact salt control these instructions. Carbonate and hydrochloride remain separate records; the adult switching instruction is not pediatric equivalence.

What to reconcile

Confirm the salt, formulation, phosphate concentration, current binder, GI history and interacting medicines. Do not treat these rows as dialysis-clearance replacement doses.

2 source identities and dates

GlobalRPh RX List - RENVELA

GlobalRPh-hosted RX List | Source revision: Revision not established in selected retrieval
Adults with CKD on dialysis; binder-naive initial dosing unless otherwise stated.

Read this stored source

Sevelamer carbonate - RENVELA tablets and powder

Sanofi / manufacturer prescribing information | Source revision: 03/2023
Adults with CKD on dialysis; binder-naive initial dosing unless otherwise stated.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v6.4.

Open / share source review Open drug and compare sources

source scope and renal guidance

Sevelamer hydrochloride - RENAGEL tablets

Before use: Sevelamer hydrochloride - RENAGEL tablets

Phosphorus concentration, meals and exact salt control these instructions. Carbonate and hydrochloride remain separate records; the adult switching instruction is not pediatric equivalence.

What to reconcile

Confirm the salt, formulation, phosphate concentration, current binder, GI history and interacting medicines. Do not treat these rows as dialysis-clearance replacement doses.

2 source identities and dates

GlobalRPh RX List - RENAGEL

GlobalRPh-hosted RX List | Source revision: Revision not established in selected retrieval
Adults with CKD on dialysis; binder-naive initial dosing unless otherwise stated.

Read this stored source

Sevelamer hydrochloride - RENAGEL tablets

Sanofi / manufacturer prescribing information | Source revision: 12/2023
Adults with CKD on dialysis; binder-naive initial dosing unless otherwise stated.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v6.4.

Open / share source review Open drug and compare sources

scope and applicability

Sildenafil - REVATIO for pulmonary arterial hypertension

PAH and erectile-dysfunction instructions are not interchangeable

The selected REVATIO renal statement is a PAH instruction. The separate sildenafil record contains erectile-dysfunction material.

What to reconcile

Match indication and formulation; do not average starting-dose and no-adjustment instructions.

1 source identities and dates

GlobalRPh RX List - REVATIO

GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Sildenafil in the REVATIO pulmonary arterial hypertension context; adult renal implications. Do not substitute VIAGRA erectile-dysfunction instructions or infer an oral-to-injection conversion.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v5.3.

Open / share source review Open drug and compare sources Sildenafil - erectile dysfunction - related, not interchangeable

qualitative precaution

Silver sulfadiazine - SILVADENE 1% cream

A topical cream still warrants accumulation and monitoring review

The selected source describes impaired elimination and monitoring in extensive burns without a numerical renal reduction.

What to reconcile

Preserve qualitative safety information instead of classifying missing numerical dosing as no renal concern.

1 source identities and dates

GlobalRPh RX List - SILVADENE

GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
SILVADENE silver sulfadiazine 1% topical cream in burn care; not systemic sulfadiazine.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v5.3.

Open / share source review Open drug and compare sources

treatment phase and formulation

Sitagliptin / metformin extended-release (ZITUVIMET XR)

Initiation, continuation and IR combination limits differ

The XR source permits a benefit-risk review of continued therapy with reduced sitagliptin exposure below 45, but discourages new initiation in its lower band. The IR product cannot deliver that lower combination regimen.

What to reconcile

Check the source's inconsistent exactly-45 initiation wording, the below-30 contraindication and each component. Do not use an XR continuation rule to initiate IR treatment.

1 source identities and dates

GlobalRPh RX List - ZITUVIMET XR

GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
ZITUVIMET XR fixed combination; not immediate-release ZITUVIMET.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v3.7.

Open / share source review Open drug and compare sources Sitagliptin / metformin immediate-release (ZITUVIMET) - related, not interchangeable

label vs institutional guidance

Sitagliptin / metformin immediate-release (Janumet)

JANUMET label versus institutional metformin contrast policy

JANUMET labeling advises interruption for eGFR 30-60 around iodinated contrast. UCSF allows metformin continuation for IV contrast at eGFR at least 30 without AKI. The two also describe arterial procedures differently.

What to reconcile

Document the institutional policy and contrast route. This disagreement does not override JANUMET suitability or its sitagliptin component. The UCSF page cites an older ACR edition; no latest-edition claim is made.

2 source identities and dates

GlobalRPh RX List - JANUMET

GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Adult sitagliptin/metformin immediate-release fixed combination; not JANUMET XR or either separate ingredient.

Read this stored source

UCSF Radiology: metformin around iodinated contrast

UCSF Radiology | Source revision: Page cites ACR Manual version 10.3 (2017); no edition update inferred from retrieval date.
Institutional metformin contrast guidance; combination-product restrictions remain separate.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v3.6.

Open / share source review Open drug and compare sources Sitagliptin - related, not interchangeable Sitagliptin / metformin extended-release (Janumet XR) - related, not interchangeable

qualitative sodium precaution

Sodium phenylbutyrate - BUPHENYL tablets and powder

Sodium burden matters without a clearance table

The source retains severe-renal and sodium-retention cautions without a numeric adjustment schedule.

What to reconcile

Review sodium load and the metabolic-treatment plan; do not improvise a percentage reduction.

1 source identities and dates

GlobalRPh RX List - BUPHENYL

GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
BUPHENYL tablets/powder for urea-cycle-disorder management. Not a glycerol phenylbutyrate or emergency hyperammonemia substitution.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v5.6.

Open / share source review Open drug and compare sources

monitoring scope

Sodium phenylbutyrate - OLPRUVA oral suspension

OLPRUVA: ammonia and potassium monitoring, not an invented renal reduction

The label supplies monitoring instructions but no numerical renal algorithm.

What to reconcile

Retain ammonia and potassium surveillance. Do not substitute glycerol phenylbutyrate dosing.

1 source identities and dates

GlobalRPh RX List - OLPRUVA

GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Sodium phenylbutyrate - OLPRUVA oral suspension; selected source sections only, not a complete prescribing monograph.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v4.9.

Open / share source review Open drug and compare sources Glycerol phenylbutyrate oral liquid (RAVICTI) - related, not interchangeable

contraindication and fluid management

Sodium picosulfate / magnesium oxide / citric acid - CLENPIQ oral solution

A bowel-preparation renal contraindication is not a dose-reduction table

Both selected sources contraindicate severe renal impairment; the official precautions also address hydration and fluid intolerance.

What to reconcile

Do not improvise a reduced preparation dose. Review fluid/electrolyte status and concomitant renal-risk medicines.

2 source identities and dates

GlobalRPh RX List - CLENPIQ

GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
CLENPIQ ready-to-drink bowel preparation; not interchangeable with other magnesium-containing laxatives or preparation formulations.

Read this stored source

Sodium picosulfate / magnesium oxide / citric acid - CLENPIQ oral solution

DailyMed / Ferring Pharmaceuticals Inc. | Source revision: 10/2024
CLENPIQ ready-to-drink bowel preparation; not interchangeable with other magnesium-containing laxatives or preparation formulations.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v5.9.

Open / share source review Open drug and compare sources

dialysis timing

Sodium zirconium cyclosilicate - LOKELMA oral suspension

The chronic-HD schedule belongs to nondialysis days

The selected dialysis regimen uses nondialysis-day administration and predialysis potassium after the long interval.

What to reconcile

Do not substitute post-HD dosing or treat this schedule as emergency management of life-threatening hyperkalemia.

1 source identities and dates

GlobalRPh RX List - LOKELMA

GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Sodium zirconium cyclosilicate - LOKELMA oral suspension; selected renal passages, not a complete prescribing monograph.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v5.3.

Open / share source review Open drug and compare sources

What is not established by this directory

Only documented issues are searchable here. Absence of a note is not agreement. A label mirror and the original label are not independent corroboration, and a source's retrieval date is not its revision date.

See source and A-Z review status Home / all drugs